Clinical Trials Directory

Trials / Completed

CompletedNCT00656565

Inspiratory Flow and Volumes in Bronchiectatics

Inspiratory Flow Rates and Volumes in Subjects With Bronchiectasis Using Low and High Resistance Dry Powder Inhaler Devices

Status
Completed
Phase
Study type
Observational
Enrollment
15 (estimated)
Sponsor
Syntara · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Adequate administration of drugs via dry powder inhalers is dependent on adequate inspiratory flow rates and volumes. These vary according to the device being used and its resistance. The dry powder inhaler device under investigation is a device approved by the Therapeutic Goods Administration (ARTG no. 196255) for use with dry powder mannitol. Dry powder mannitol is currently being investigated as a treatment for bronchiectasis. We wish to measure the inspiratory flow characteristics of both the low and high resistance devices amongst a group of subjects with bronchiectasis. We propose that the majority of subjects investigated with varying lung function will achieve adequate flow during a controlled inspiration.

Conditions

Timeline

Start date
2008-06-01
Primary completion
2008-07-01
Completion
2008-07-01
First posted
2008-04-11
Last updated
2008-08-06

Locations

1 site across 1 country: Australia

Source: ClinicalTrials.gov record NCT00656565. Inclusion in this directory is not an endorsement.